Tech Company Inital Public Offerings
Atreca IPO
Operating out of Redwood City, Atreca is now a public company.
Transaction Overview
Company Name
Announced On
6/19/2019
Transaction Type
IPO
Amount
$125,000,000
Proceeds Purpose
Per the firm's latest filing, it plans to use the net proceeds from the IPO as follows: approximately $45 million to fund the development of ATRC-101 through the dose-escalation portion of our Phase 1b clinical trial and a portion of our currently planned protocol amendments to pursue combination studies and expansion cohorts; approximately $65 million to fund our ongoing efforts to develop additional clinical candidates from our discovery platform; and the remaining proceeds for continued development and utilization of our discovery platform, hiring of additional personnel, capital expenditures, costs of operating as a public company and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
500 Saginaw Dr.
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
Atreca (Nasdaq: BCEL) develops a technology to identify the set of antibodies produced during an immune response, without prior knowledge of an antigen.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/19/2019: AnyVision venture capital transaction
Next: 6/19/2019: RAPT Therapeutics venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs